Ligand to Participate in March Investor Conferences
Rhea-AI Summary
Ligand (Nasdaq: LGND) said senior management will attend three investor conferences in March 2026, offering one-on-one meetings and two public presentations. Presentations are scheduled at the 38th Annual ROTH Conference on March 23, 2026 at 1:00 p.m. PT and the Nordic-American Healthcare Conference on March 25, 2026 at 3:45 p.m. ET. Investors may request one-on-one meetings through their Leerink, ROTH, or NAHC representative.
Positive
- None.
Negative
- None.
News Market Reaction – LGND
On the day this news was published, LGND gained 2.31%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows only MIRM moving (-0.90%, down) with no related news, while LGND had a modest 0.83% gain earlier. This points to stock-specific dynamics rather than a coordinated biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | Earnings results | Positive | +2.5% | Reported strong Q4 and 2025 results with royalty growth and reaffirmed 2026 guidance. |
| Feb 12 | Earnings date notice | Neutral | -2.3% | Announced timing and access details for upcoming Q4 and full-year 2025 results call. |
| Feb 04 | Conference participation | Neutral | -0.3% | Management scheduled for virtual fireside chat and one-on-one investor meetings. |
| Dec 09 | Investor day, guidance | Positive | +0.6% | Hosted Investor Day, introduced 2026 guidance and multi-year royalty growth outlook. |
| Nov 06 | Earnings, guidance raise | Positive | +9.4% | Reported strong Q3 2025, raised 2025 core revenue and EPS guidance, detailed royalty gains. |
Recent news—especially earnings and guidance—has generally seen positive or mildly positive price reactions, with no instances of clear negative divergence.
Over the past several months, Ligand has highlighted strong financial performance and active investor engagement. Earnings updates on Nov 6, 2025 and Feb 26, 2026 showed robust revenue growth and raised or reaffirmed guidance, both followed by positive stock reactions. Investor-focused events such as the 2025 Investor Day and prior conference participation drew modest, generally stable responses. Today’s announcement of multiple March conferences fits this pattern of consistent outreach rather than a new financial or clinical inflection point.
Market Pulse Summary
This announcement outlines Ligand’s upcoming presence at several March investor conferences, emphasizing continued outreach through presentations and one-on-one meetings. Recent history shows the company pairing active investor communication with strong reported financials and reiterated guidance. While today’s news does not introduce new revenue or clinical data, investors may watch for any incremental commentary from these events and compare it against prior disclosures and guidance trajectories highlighted in recent earnings and Investor Day materials.
AI-generated analysis. Not financial advice.
JUPITER, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences:
- Leerink Partners Global Healthcare Conference (Miami): Management will participate in one-on-one meetings March 11, 2026
- 38th Annual ROTH Conference (Dana Point, Calif.): Management will present at 1:00 p.m. PT on March 23, 2026
- Nordic-American Healthcare Conference 2026 (New York): Management will present at 3:45 p.m. ET on March 25, 2026
Ligand management is scheduled to host one-on-one meetings with investors and attendees during these conferences. Investors interested in arranging one-on-one meetings should contact their Leerink, ROTH, or NAHC representative.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X and LinkedIn.
We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.
Contacts
Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761
Media:
Kellie Walsh
media@ligand.com
(914) 315-6072
FAQ
When will Ligand (LGND) present at the 38th Annual ROTH Conference in March 2026?
What is Ligand's (LGND) schedule for the Nordic-American Healthcare Conference in March 2026?
How can investors arrange one-on-one meetings with Ligand (LGND) management in March 2026?
Which March 2026 conferences will Ligand (LGND) management attend and present at?
Will Ligand (LGND) hold presentations and one-on-one meetings at the Leerink Partners Global Healthcare Conference?
